Abdominal aortic aneurysms: current management.

Optimal management of abdominal aortic aneurysm (AAA) remains a challenging surgical problem. Over the last decade surgical and anesthetic improvements have provided perioperative mortality in the 2% range, when elective AAA repair was performed in single Institutions with large vascular experience. However, community- or national-based mortality rates for elective AAA surgery may be as high as 11% or more. Mortality rates associated with ruptured aneurysms remain as high as 90%. AAA prophylactic resection should be indicated when the risk of rupture exceeds the surgical risk. Although the risk of rupture correlates strongly with the diameter of the AAA, there is evidence that other factors can increase the rupture risk: hypertension, chronic pulmonary disease, aneurysm morphology, etc. Establishing a single threshold diameter for AAA repair appears naive. Moreover, AAA primarily affects older patients with other comorbidities that shorten life expectancy and increase perioperative risks: coronary artery disease, renal and pulmonary insufficiency, peripheral artery disease, etc. So that, proper management of individual AAA is based on balancing the perioperative risk, the risk of rupture, and life expectancy. In the subgroup of young healthy patients with additional risk factors for AAA rupture, elective repair at a smaller size (4 to 5.5 cm) may be beneficial if low surgical risk can be assured. In the last decade endovascular repair for AAA treatment has emerged. These less invasive endovascular techniques for AAA repair offer some advantages in terms of reduced patient stress, analgesic requirement, respiratory dysfunction, blood loss, need for intensive care and reduced hospitalization with an early technical success similar to that of open surgical treatment. However, there are no prospective, randomized studies evaluating endovascular treatment of AAA. Moreover, long-term results on the durability of these new techniques are needed to assess endovascular repair as an alternative treatment to prevent the risk of AAA rupture.